SCHEMBL14404518

SCHEMBL14404518

NCC(=O)c1cccc(F)c1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 5/20 0.61
▸ CES1 P23141 5/20 0.61
▸ BCHE P06276 1/20 0.61
▸ HPGD P15428 1/20 0.47
▸ ALB P02768 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ ERCC5 P28715 1/20 0.42
▸ FEN1 P39748 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ KAT6A Q92794 1/20 0.41
▸ DRD2 P14416 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ HMGB1 P09429 1/20 0.37
▸ CTNNB1 P35222 2/20 0.37
▸ WNT3A P56704 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30839516 1.00 CES2 (0.61) CES2CES1BCHEHPGDALB
SCHEMBL6503771 0.83 PTPN1 (0.58) CES2CES1BCHEHPGDPTPN1
SCHEMBL14396511 0.82 CES2 (0.63) CES2CES1BCHEHPGDALB
Hydrochloric Acid SCHEMBL30301349 0.82 PTPN1 (0.56) CES2CES1BCHEHPGDPTPN1
Hydrochloric Acid SCHEMBL1653086 0.82 PTPN1 (0.56) CES2CES1BCHEHPGDPTPN1
SCHEMBL13722818 0.82 CES2 (0.63) CES2CES1BCHEHPGDALB
SCHEMBL15990788 0.82 CES2 (0.63) CES2CES1BCHEHPGDALB
SCHEMBL7771468 0.81 CES2 (0.57) CES2CES1BCHEHPGDALB
SCHEMBL633282 0.80 CES2 (0.61) CES2CES1BCHEHPGDALB
SCHEMBL3058748 0.80 CES2 (0.61) CES2CES1BCHEHPGDALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345678-B2 Benzopyrazole compound used as RHO kinase inhibitor MEDSHINE DISCOVERY INC. (CN) 2022-05-31 — — US disclosed
US-20210371393-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2021-12-02 — — US disclosed
EP-3782987-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR Medshine Discovery Inc. (CN) 2021-02-24 — — EP disclosed
WO-2019201297-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR 南京明德新药研发有限公司 2019-10-24 — — WO disclosed
WO-2007120591-A1 PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST MERCK & CO., INC. (US) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345678-B2 Benzopyrazole compound used as RHO kinase inhibitor ROCK1, ROCK2, CIT CES2 4205/4885CES1 1510/4885BCHE 3106/4885
US-20210371393-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR ROCK1, ROCK2, CIT CES2 4205/4885CES1 1510/4885BCHE 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback